Pfizer and 23andMe to research bowel diseasePfizer and US-based personal genetics company 23andMe are partnering on research into Inflammatory Bowel Disease (IBD). They plan Share XPfizer and 23andMe to research bowel diseasehttps://pharmaphorum.com/news/pfizer-and-23andme-to-research-bowel-disease/
Prosensa’s muscular dystrophy programme ‘back on track’At the start of the year, prospects for Prosensa’s Duchenne muscular dystrophy (DMD) drug drisapersen looked decidedly shaky, Share XProsensa’s muscular dystrophy programme ‘back on track’https://pharmaphorum.com/news/prosensas-muscular-dystrophy-programme-back-on-track/
Claims of GSK corruption in Syria widenGlaxoSmithKline is facing yet more scrutiny over its business practices, with claims emerging of bribery in its Syrian Share XClaims of GSK corruption in Syria widenhttps://pharmaphorum.com/news/claims-of-gsk-corruption-in-syria-widen/
Zmapp to treat Liberian Ebola victimsThe experimental drug Zmapp is to be used to treat Liberian Ebola victims, despite the fact that it Share XZmapp to treat Liberian Ebola victimshttps://pharmaphorum.com/news/zmapp-to-treat-liberian-ebola-victims/
EU approval for Bayer’s Eylea in diabetic macular oedemaBayer HealthCare’s Eylea (aflibercept solution for injection into the eye) has been approved by the European Commission for Share XEU approval for Bayer’s Eylea in diabetic macular oedemahttps://pharmaphorum.com/news/eu-approval-for-bayer-s-eylea-in-diabetic-macular-oedema/
Astellas taps UK scientists for pancreatic cancer leadsAstellas has joined forces with medical researchers in the UK to develop therapies that – somewhat counter-intuitively – Share XAstellas taps UK scientists for pancreatic cancer leadshttps://pharmaphorum.com/news/astellas-taps-uk-scientists-for-pancreatic-cancer-leads/
FDA relaxes restrictions on Ebola drugA block on clinical testing of a drug for Ebola developed by Tekmira Pharmaceuticals has been downgraded in Share XFDA relaxes restrictions on Ebola drughttps://pharmaphorum.com/news/fda-relaxes-restrictions-on-ebola-drug/
EU approves Roche’s Avastin in ovarian cancerRoche is celebrating what it says is the first new treatment option in Europe for women with the Share XEU approves Roche’s Avastin in ovarian cancerhttps://pharmaphorum.com/news/eu-approves-roche-s-avastin-in-ovarian-cancer/
Roche returns to gene silencing with Santaris acquisitionFour years ago, Roche’s decision to stop research on RNA interference (RNAi) was seen as a major setback Share XRoche returns to gene silencing with Santaris acquisitionhttps://pharmaphorum.com/news/roche-returns-to-gene-silencing-with-santaris-acquisition/
